Apyx Medical Corporation Common Stock APYX

$3.05 +0.66% at last close

Analyst Consensus

Consensus Rating
Buy (5 Buy · 0 Hold · 0 Sell)
Average Price Target
$6.60
Implied Upside
+116.4%
Price Target Range
$6.00 – $8.00
Analysts (12 mo)
5

Recent Analyst Actions

DateFirmActionRatingPrice Target
2026-07-13
HC Wainwright & Co.Yi Chen
Initiates coverage on Buy $7
2026-03-11
Craig-HallumMatthew Hewitt
Maintains Buy $5 → $6
2026-03-11
BTIGSam Eiber
Upgrades Neutral → Buy $6
2025-12-16
Roth CapitalKyle Bauser
Initiates coverage on Buy $6
2025-11-12
CitizensDavid Turkaly
Upgrades Market perform → Market outperform $8
2024-10-17
BTIGSam Eiber
Initiates coverage on Neutral
2024-09-16
JMP SecuritiesDavid Turkaly
Reiterates Market perform
2023-11-10
Stephens & Co.George Sellers
Maintains Overweight $8 → $5
2023-08-11
Piper SandlerMatt O'Brien
Maintains Overweight $4 → $5
2023-07-14
Stephens & Co.George Sellers
Initiates coverage on Overweight $8
2023-06-15
Lake StreetFrank Takkinen
Maintains Buy $6 → $9
2023-05-24
JMP SecuritiesDavid Turkaly
Reiterates Market perform
2023-05-12
Lake StreetFrank Takkinen
Maintains Buy $5 → $6
2022-12-08
Lake StreetFrank Takkinen
Assumes Buy $5
2022-08-12
Piper SandlerMatt O'Brien
Maintains Overweight $6 → $12
2022-07-19
Lake StreetKyle Bauser
Maintains Buy $14 → $17
2022-05-20
Lake StreetKyle Bauser
Initiates coverage on Buy $12
2021-08-13
JMP SecuritiesDavid Turkaly
Maintains Market outperform $12 → $14
2020-05-12
JMP SecuritiesDavid Turkaly
Maintains Market outperform $7 → $5
2019-11-12
Piper Sandler
Maintains Overweight $8 → $10
2019-04-02
JMP SecuritiesDavid Turkaly
Maintains Market outperform $12 → $8

Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.

Key Stats

Last Close
$3.05
Market Cap
$132.69 million
52-Week Range
$1.59 $5.08
Average Volume
99K shs

Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.